BridgeBio Oncology Therapeutics
Closed (deSPAC)Profile in progress
- What it is
- A private company preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Helix Acquisition Corp. II (HLXB) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
What the company says about itself
Web research — not auditedBridgeBio Oncology Therapeutics (BBOT) aims to transform the lives of patients with cancers driven by RAS and PI3Kα. The company utilizes expert understanding of RAS signaling biology to inform rational drug design, focusing on maximizing target inhibition by inhibiting the active ON state. Their approaches include selective inhibition of RAS-driven PI3K activation and targeting a broad spectrum of KRAS mutants in both ON and OFF states.
- Markets:
- Oncology | Cancer
[WEB-INTEL 2026-08-26] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Helix Acquisition Corp. II raised $184 million in its initial public offering on February 9, 2024." [https://www.stocktitan.net/news/HLXB/helix-acquisition-corp-ii-and-bridge-bio-oncology-therapeutics-p2bzo89pprr5.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The extraordinary general meeting of Helix shareholders is scheduled for August 4, 2025." [https://www.stocktitan.net/news/HLXB/helix-acquisition-corp-ii-and-bridge-bio-oncology-therapeutics-p2bzo89pprr5.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The record date is June 30, 2025." [https://www.stocktitan.net/news/HLXB/helix-acquisition-corp-ii-and-bridge-bio-oncology-therapeutics-p2bzo89pprr5.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II ... are expected to be $450 million, Business combination is expected to be completed in the third quarter of 2025" [https://bbotx.com/news/bridgebio-oncology-therapeutics-bbot-and-helix-acquisition-corp-ii-announce-business-combination-agreement-to-create-publicly-listed-biotechnology-company-advancing-a-pipeline-of-ras-and-pi3k%CE%B1/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "BridgeBio Oncology merges with Helix Acquisition Corp. II in a $450M SPAC deal, securing $196M from trust account and $260M in PIPE financing" [https://trial.medpath.com/news/bridgebio-oncology-secures-450m-spac-deal-to-advance-kras-inhibitor-pipeline]
Source: https://bbotx.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
BridgeBio Oncology Therapeutics is merging with Helix Acquisition Corp. II (HLXB) currently marked Closed (deSPAC).
| Headline equity value | — |
| PIPE | ≈ $261M · unsourced |
Structure per SEC accession(s) 0001213900-25-056321. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is BridgeBio Oncology Therapeutics going public?
BridgeBio Oncology Therapeutics has an approved merger with the SPAC Helix Acquisition Corp. II (HLXB). Deal status: Closed (deSPAC).
Does BridgeBio Oncology Therapeutics have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.